Clinical Trial

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Study acronym: MoonRISe-3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
Protocol Amendment History 1 change
notable Trial sites expanded: 104 -> 108 locations 2026-05-09
Trial Details
NCT Number NCT06919965
Lead Sponsor Janssen Research & Development, LLC
Conditions Non-Muscle Invasive Bladder Neoplasms
Enrollment 220 participants
Start Date 2025-09-10
Primary Completion 2028-04-06 (estimated)
Study Completion 2032-03-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-31